FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments - FDA Press Releases

FDA granted accelerated approval to Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with triple-negative breast cancer that has spread. Patients must have received at least two prior therapies.

from FDA Press Releases RSS Feed https://ift.tt/2Vvpmd7
via IFTTT